Effects of Bifidobacterium-based interventions on patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials
Digestive Diseases · 2026-11-05
DOI: 10.1159/ddi/acnag015 ↗Abstract
Abstract Background: Bifidobacterium has showcased potential benefits in managing irritable bowel syndrome (IBS) symptoms. Methods: We systematically searched online databases up until 1 December 2025, to identify randomized, double-blind, placebo-controlled trials investigating the efficacy of Bifidobacterium-based or Bifidobacterium-containing preparations in IBS patients. Pooled analyses of the effects of these interventions on IBS symptom relief were calculated using a random-effects model. Subgroup analyses were conducted based on different regions, doses, and treatment durations. Results: Eight RCTs encompassing 1,304 patients were identified. Bifidobacterium-based interventions demonstrated significant improvements in overall response rate (RR: 1.99; 95% CI: 1.63–2.43; P < 0.00001), abdominal pain relief (RR: 2.09; 95% CI: 1.36–3.24; P = 0.0009), and subjective relief (RR: 1.62; 95% CI: 1.28–2.05; P < 0.0001). Significant benefits were observed in both adult (RR: 1.94; 95% CI: 1.58–2.40; P < 0.00001) and pediatric cohorts (RR: 2.86; 95% CI: 1.33–6.15; P = 0.007). However, subgroup comparisons showed comparable efficacy between daily dosages of < 10¹⁰ and ≥ 10¹⁰ CFU (P = 0.65) and between treatment durations of < 8 and ≥ 8 weeks (P = 0.33). Conclusions: Bifidobacterium-based interventions effectively alleviate IBS symptoms, particularly abdominal pain and subjective discomfort, in both adults and children. However, current evidence does not demonstrate superiority for specific doses or extended durations, precluding definitive conclusions regarding optimal posology. Systematic review registration: PROSPERO registration no. CRD420251252390.
EUVIMED